Comparative Pharmacology
Head-to-head clinical analysis: DARICON versus DETROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARICON versus DETROL.
DARICON vs DETROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daricon (oxyphencyclimine) is a competitive antagonist of muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses. It reduces gastrointestinal motility, gastric acid secretion, and smooth muscle spasm by blocking cholinergic activity at effector cells.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
5 mg orally three times daily. Maximum dose: 15 mg per day.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours; clinical context: allows twice-daily dosing
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Renal (70% unchanged, 30% as metabolites); biliary/fecal (10%)
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Category C
Category C
Anticholinergic
Anticholinergic